Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial-Reference-Cited by-同舟云学术

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Published:2015-05 Issue:5 Volume:16 Page:509-521
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Loriot Yohann,Miller Kurt,Sternberg Cora N,Fizazi Karim,De Bono Johann S,Chowdhury Simon,Higano Celestia S,Noonberg Sarah,Holmstrom Stefan,Mansbach Harry,Perabo Frank G,Phung De,Ivanescu Cristina,Skaltsa Konstantina,Beer Tomasz M,Tombal Bertrand

Publisher

Elsevier BV

Subject

Oncology

Reference49 articles.

1. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality;Scosyrev;Cancer,2012

2. Risk profiles of prostate cancers identified from UK primary care using national referral guidelines;Serag;Br J Cancer,2012

3. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures;Huang;J Hematol Oncol,2012

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”;Cell Reports Medicine;2024-06

2. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review;Frontiers in Oncology;2024-04-15

3. Novel hormonal therapy versus standard of care—A registry-based comparative effectiveness evaluation for mCRPC-patients;PLOS ONE;2024-02-14

4. Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns;Therapeutic Advances in Medical Oncology;2024-01

5. Quality of life for androgen receptor targeted agents in patients with metastatic castration resistant prostate cancer;Bratislava Medical Journal;2024